Budgeting for Opioid Addiction Treatment Act

S 2559, the *Budgeting for Opioid Addiction Treatment Act*, imposes a 1-cent fee per milligram on opioid pain relievers sold by manufacturers, producers, or importers, while excluding medications used for addiction treatment and non-opioid ingredients. It requires the Secretary of Health and Human Services to establish rebates or discounts for cancer patients, hospice patients, and others with specific pain needs to prevent them from bearing the fee cost. Revenue from the fee (after rebates) must be directed to states for opioid addiction treatment programs, including building facilities, expanding residential care, supporting mental health providers in underserved areas, and housing for families affected by addiction. The bill mandates a congressional report within two years assessing the fee’s impact on opioid costs, patient access, and how funds improve treatment services.